Humacyte terminates $80M at-the-market offering agreement with Jefferies

Humacyte, Inc.

Agreement allowed sale of up to $80M in common stock via Jefferies as agent.
Termination notice delivered November 21, 2025; effective 10 days later.
Company is not subject to any termination penalties.
No new financing or replacement agreement announced.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.